### Section 13: OUTCOME MEASUREMENT (`/outcomes`)
**Purpose:** Show we prove transformation works. Science-backed, measurable results.

#### Clinical Measurement Framework
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                                                                             â”‚
â”‚                      MEASURING TRANSFORMATION                               â”‚
â”‚                                                                             â”‚
â”‚   We don't just claim transformation. We measure it.                       â”‚
â”‚                                                                             â”‚
â”‚   VALIDATED CLINICAL SCALES                                                 â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                â”‚
â”‚                                                                             â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”           â”‚
â”‚   â”‚     PCL-5       â”‚  â”‚     PHQ-9       â”‚  â”‚     GAD-7       â”‚           â”‚
â”‚   â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚  â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚  â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚           â”‚
â”‚   â”‚  PTSD Symptoms  â”‚  â”‚  Depression     â”‚  â”‚  Anxiety        â”‚           â”‚
â”‚   â”‚                 â”‚  â”‚                 â”‚  â”‚                 â”‚           â”‚
â”‚   â”‚  20-item scale  â”‚  â”‚  9-item scale   â”‚  â”‚  7-item scale   â”‚           â”‚
â”‚   â”‚  Gold standard  â”‚  â”‚  Clinical std   â”‚  â”‚  Clinical std   â”‚           â”‚
â”‚   â”‚  for trauma     â”‚  â”‚  for depression â”‚  â”‚  for anxiety    â”‚           â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜           â”‚
â”‚                                                                             â”‚
â”‚   BIOMETRIC TRACKING                                                        â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                       â”‚
â”‚                                                                             â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”           â”‚
â”‚   â”‚      HRV        â”‚  â”‚   Sleep Data    â”‚  â”‚  Blood Panels   â”‚           â”‚
â”‚   â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚  â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚  â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚           â”‚
â”‚   â”‚  Heart Rate     â”‚  â”‚  Quality &      â”‚  â”‚  Inflammation   â”‚           â”‚
â”‚   â”‚  Variability    â”‚  â”‚  Duration       â”‚  â”‚  Hormones       â”‚           â”‚
â”‚   â”‚                 â”‚  â”‚                 â”‚  â”‚  Metabolic      â”‚           â”‚
â”‚   â”‚  Nervous system â”‚  â”‚  Recovery       â”‚  â”‚  markers        â”‚           â”‚
â”‚   â”‚  regulation     â”‚  â”‚  indicator      â”‚  â”‚                 â”‚           â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜           â”‚
â”‚                                                                             â”‚
â”‚   MEASUREMENT POINTS                                                        â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                       â”‚
â”‚   ğŸ“ Pre-arrival baseline (4-8 weeks before)                               â”‚
â”‚   ğŸ“ Arrival assessment (Day 1)                                            â”‚
â”‚   ğŸ“ Mid-program check-in (Day 7-14)                                       â”‚
â”‚   ğŸ“ Departure assessment (Final day)                                      â”‚
â”‚   ğŸ“ 30-day follow-up                                                      â”‚
â”‚   ğŸ“ 90-day follow-up                                                      â”‚
â”‚   ğŸ“ 6-month integration check                                             â”‚
â”‚   ğŸ“ 12-month annual review                                                â”‚
â”‚                                                                             â”‚
â”‚   OUTCOME TARGETS                                                          â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                          â”‚
â”‚   â€¢ PCL-5: 30%+ reduction in trauma symptoms                               â”‚
â”‚   â€¢ PHQ-9: 40%+ improvement in depression scores                           â”‚
â”‚   â€¢ GAD-7: 35%+ reduction in anxiety                                       â”‚
â”‚   â€¢ HRV: 20%+ improvement in nervous system regulation                     â”‚
â”‚   â€¢ Guest satisfaction: NPS 80+                                            â”‚
â”‚   â€¢ 12-month maintenance: 70%+ sustaining gains                            â”‚
â”‚                                                                             â”‚
â”‚   This data becomes our competitive moat.                                  â”‚
â”‚   No competitor is collecting outcomes at this level.                      â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

#### Research Evidence Base

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                                                                             â”‚
â”‚   SCIENTIFIC FOUNDATION: PUBLISHED RESEARCH                                â”‚
â”‚                                                                             â”‚
â”‚   IBOGAINE EFFICACY STUDIES                                                â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   â€¢ Noller et al. (2018) - "Ibogaine Treatment Outcomes"                  â”‚
â”‚     Journal: American Journal of Drug and Alcohol Abuse                    â”‚
â”‚     N=30 participants, 12-month follow-up                                  â”‚
â”‚     Results: 50% abstinence from opioids at 12 months                      â”‚
â”‚     Safety: Zero serious adverse events with medical screening             â”‚
â”‚                                                                             â”‚
â”‚   â€¢ Brown & Alper (2018) - "Treatment of Opioid Use Disorder"              â”‚
â”‚     Journal: Current Drug Abuse Reviews                                    â”‚
â”‚     Review: 19 observational studies, 768 total participants               â”‚
â”‚     Conclusion: Ibogaine shows promise for addiction treatment             â”‚
â”‚                                                                             â”‚
â”‚   â€¢ Mash et al. (2018) - "Ibogaine Pharmacokinetics"                      â”‚
â”‚     Journal: Journal of Ethnopharmacology                                  â”‚
â”‚     Finding: Safe metabolic profile with proper screening                  â”‚
â”‚     Critical: EKG screening prevents cardiac complications                 â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   TRAUMA & PTSD TREATMENT EVIDENCE                                         â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   â€¢ Mitchell et al. (2021) - "MDMA-Assisted Therapy for PTSD"              â”‚
â”‚     Journal: Nature Medicine                                               â”‚
â”‚     N=90, Phase 3 trial                                                    â”‚
â”‚     Results: 67% no longer met PTSD criteria (vs 32% placebo)              â”‚
â”‚     Relevance: Psychedelic-assisted therapy efficacy established           â”‚
â”‚                                                                             â”‚
â”‚   â€¢ Carhart-Harris et al. (2021) - "Psilocybin for Depression"             â”‚
â”‚     Journal: New England Journal of Medicine                               â”‚
â”‚     N=59, compared to escitalopram                                         â”‚
â”‚     Results: Non-inferior to SSRI, faster onset                            â”‚
â”‚     Relevance: Validates psychedelic therapy model                         â”‚
â”‚                                                                             â”‚
â”‚   â€¢ van der Kolk (2014) - "The Body Keeps the Score"                       â”‚
â”‚     Evidence: Somatic approaches essential for trauma                      â”‚
â”‚     Application: Validates our polyvagal/somatic framework                 â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   BIOMETRIC OUTCOME MEASURES                                               â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   â€¢ Shaffer et al. (2014) - "HRV as Biomarker for Health"                  â”‚
â”‚     Journal: Frontiers in Public Health                                    â”‚
â”‚     Evidence: HRV correlates with emotional regulation, resilience         â”‚
â”‚     Application: Primary biometric in our measurement framework            â”‚
â”‚                                                                             â”‚
â”‚   â€¢ Kaufmann et al. (2016) - "Heart Rate Variability Biofeedback"          â”‚
â”‚     Journal: Applied Psychophysiology & Biofeedback                        â”‚
â”‚     Finding: HRV training improves PTSD symptoms                           â”‚
â”‚     Relevance: Supports our nervous system optimization approach           â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   INTEGRATION & LONG-TERM OUTCOMES                                         â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   â€¢ Wolff et al. (2020) - "Psychedelic Integration"                        â”‚
â”‚     Journal: Journal of Psychoactive Drugs                                 â”‚
â”‚     Finding: Integration predicts long-term benefit maintenance            â”‚
â”‚     Application: Why we invest heavily in 3-12 month post-care             â”‚
â”‚                                                                             â”‚
â”‚   â€¢ Erritzoe et al. (2018) - "Psilocybin with Psychological Support"       â”‚
â”‚     Journal: Psychopharmacology                                            â”‚
â”‚     Finding: Therapeutic support essential for positive outcomes           â”‚
â”‚     Relevance: Validates our facilitator + therapist model                 â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

#### Outcome Data Collection & Analysis Plan

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                                                                             â”‚
â”‚   DATA COLLECTION METHODOLOGY                                              â”‚
â”‚                                                                             â”‚
â”‚   QUANTITATIVE MEASURES (Every Guest)                                      â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   Psychological:                                                           â”‚
â”‚   â€¢ PCL-5 (PTSD Checklist, 20 items): 8 measurement points                 â”‚
â”‚   â€¢ PHQ-9 (Depression, 9 items): 8 measurement points                      â”‚
â”‚   â€¢ GAD-7 (Anxiety, 7 items): 8 measurement points                         â”‚
â”‚   â€¢ WHO-5 (Well-being, 5 items): 8 measurement points                      â”‚
â”‚   â€¢ NPS (Net Promoter Score): Post-departure, 6-month                      â”‚
â”‚                                                                             â”‚
â”‚   Biometric (Continuous):                                                  â”‚
â”‚   â€¢ HRV: Daily (Oura Ring or Whoop strap) - 90 days pre, during, 180 post  â”‚
â”‚   â€¢ Sleep: Daily metrics (duration, deep sleep %, REM %)                   â”‚
â”‚   â€¢ Resting heart rate: Daily                                              â”‚
â”‚   â€¢ Activity levels: Daily step count, exercise minutes                    â”‚
â”‚                                                                             â”‚
â”‚   Laboratory (Selective):                                                  â”‚
â”‚   â€¢ Baseline blood panel: Pre-arrival                                      â”‚
â”‚     - CBC, CMP, lipids, HbA1c, hs-CRP (inflammation)                       â”‚
â”‚     - Cortisol (stress marker), DHEA, testosterone                         â”‚
â”‚   â€¢ Follow-up panel: 90-day (if guest opts in)                             â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   QUALITATIVE MEASURES (Subset of Guests)                                  â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   â€¢ Semi-structured interviews (30-60 min)                                 â”‚
â”‚     Timeline: Pre-arrival, departure, 30-day, 6-month, 12-month            â”‚
â”‚     Topics: Life changes, relationship shifts, career impact               â”‚
â”‚   â€¢ Written reflections (journal entries)                                  â”‚
â”‚     Prompts provided via app, analyzed for themes                          â”‚
â”‚   â€¢ Video testimonials (with consent)                                      â”‚
â”‚     Timeline: 3-month, 6-month, 12-month                                   â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   DATA MANAGEMENT & PRIVACY                                                â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   Platform: REDCap (Research Electronic Data Capture)                      â”‚
â”‚   â€¢ HIPAA-compliant, industry standard for clinical research               â”‚
â”‚   â€¢ IRB-approved data collection workflows                                 â”‚
â”‚   â€¢ De-identified datasets for analysis                                    â”‚
â”‚                                                                             â”‚
â”‚   Privacy Protections:                                                     â”‚
â”‚   â€¢ Consent obtained for research participation (opt-in)                   â”‚
â”‚   â€¢ Data anonymized for publication (no PII)                               â”‚
â”‚   â€¢ Secure storage (encrypted at rest and in transit)                      â”‚
â”‚   â€¢ Access controls (only authorized researchers)                          â”‚
â”‚                                                                             â”‚
â”‚   Data Ownership:                                                          â”‚
â”‚   â€¢ Guest owns their personal data (can request deletion)                  â”‚
â”‚   â€¢ Company owns de-identified aggregate data                              â”‚
â”‚   â€¢ Research publications require separate consent                         â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

#### Publication & Research Strategy

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                                                                             â”‚
â”‚   RESEARCH ROADMAP (3-Year Plan)                                           â”‚
â”‚                                                                             â”‚
â”‚   YEAR 1: Data Collection & Pilot Analysis                                â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   Q2-Q4 2026:                                                              â”‚
â”‚   â€¢ Enroll first 50 guests in outcome study                                â”‚
â”‚   â€¢ Establish data collection SOPs (Standard Operating Procedures)         â”‚
â”‚   â€¢ Hire outcomes coordinator (part-time, clinical research background)    â”‚
â”‚   â€¢ IRB approval for observational study                                   â”‚
â”‚                                                                             â”‚
â”‚   Deliverable: Internal report on first 50 guests (confidential)           â”‚
â”‚   Use: Refine protocols, identify early trends                             â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   YEAR 2: Analysis & Conference Presentations                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   Q1-Q2 2027:                                                              â”‚
â”‚   â€¢ Analyze first 150 guests (with 6-month follow-up data)                 â”‚
â”‚   â€¢ Partner with academic institution (UCSF, Johns Hopkins, NYU)           â”‚
â”‚   â€¢ Submit abstracts to conferences                                        â”‚
â”‚                                                                             â”‚
â”‚   Target Conferences:                                                      â”‚
â”‚   â€¢ MAPS Psychedelic Science (June 2027) - Poster presentation             â”‚
â”‚   â€¢ CIIS (California Institute of Integral Studies) Symposium              â”‚
â”‚   â€¢ American Psychological Association Annual Convention                   â”‚
â”‚                                                                             â”‚
â”‚   Deliverable: Conference poster/presentation                              â”‚
â”‚   Impact: Build credibility, attract research partners                     â”‚
â”‚                                                                             â”‚
â”‚   Q3-Q4 2027:                                                              â”‚
â”‚   â€¢ Draft manuscript for peer-reviewed journal                             â”‚
â”‚   â€¢ Title: "Integrated Psychedelic-Assisted Transformation:                â”‚
â”‚            Outcomes from 150 Participants"                                 â”‚
â”‚   â€¢ Co-authors: Medical Director + Academic partner                        â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   YEAR 3: Publication & Thought Leadership                                â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   Q1-Q2 2028:                                                              â”‚
â”‚   â€¢ Submit to target journal                                               â”‚
â”‚     Tier 1 targets: JAMA Psychiatry, The Lancet Psychiatry                 â”‚
â”‚     Tier 2 targets: Journal of Psychopharmacology, Psychopharmacology      â”‚
â”‚     Tier 3 targets: Journal of Psychoactive Drugs                          â”‚
â”‚   â€¢ Peer review process (6-12 months)                                      â”‚
â”‚                                                                             â”‚
â”‚   Q3-Q4 2028:                                                              â”‚
â”‚   â€¢ Publication! (press release, media outreach)                           â”‚
â”‚   â€¢ Present at MAPS, APA, other major conferences (invited talk)           â”‚
â”‚   â€¢ Launch outcomes dashboard (public, anonymized data viz)                â”‚
â”‚                                                                             â”‚
â”‚   Deliverable: Published peer-reviewed research                            â”‚
â”‚   Impact:                                                                  â”‚
â”‚   â€¢ Legitimacy (no competitor has published outcomes)                      â”‚
â”‚   â€¢ Media coverage (NYT, VICE, Tim Ferriss podcast)                        â”‚
â”‚   â€¢ Investor confidence (data-driven transformation)                       â”‚
â”‚   â€¢ Guest acquisition (proof of concept)                                   â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   ONGOING: Case Study Development                                         â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   Throughout Years 1-3:                                                    â”‚
â”‚   â€¢ Identify 5-10 exemplary transformation stories                         â”‚
â”‚   â€¢ Obtain consent for detailed case studies                               â”‚
â”‚   â€¢ Document: Pre-state, journey, post-transformation, life impact         â”‚
â”‚   â€¢ Create multimedia case studies (video + written)                       â”‚
â”‚                                                                             â”‚
â”‚   Use Cases:                                                               â”‚
â”‚   â€¢ Marketing materials (with permission)                                  â”‚
â”‚   â€¢ Investor presentations (anonymized if needed)                          â”‚
â”‚   â€¢ Training materials (for future staff)                                  â”‚
â”‚   â€¢ Book chapter contributions                                             â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

#### Data Visualization & Reporting

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                                                                             â”‚
â”‚   PUBLIC OUTCOMES DASHBOARD (Post-Publication)                             â”‚
â”‚                                                                             â”‚
â”‚   Real-time, Anonymized Guest Outcomes                                     â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   Metrics Displayed:                                                       â”‚
â”‚   â€¢ Total guests served (cumulative)                                       â”‚
â”‚   â€¢ Average PCL-5 reduction: XX% (with confidence interval)                â”‚
â”‚   â€¢ Average PHQ-9 improvement: XX%                                         â”‚
â”‚   â€¢ Average GAD-7 reduction: XX%                                           â”‚
â”‚   â€¢ Average HRV improvement: +XX ms (RMSSD)                                â”‚
â”‚   â€¢ 6-month maintenance rate: XX% (guests sustaining gains)                â”‚
â”‚   â€¢ Net Promoter Score: XX                                                 â”‚
â”‚                                                                             â”‚
â”‚   Visualizations:                                                          â”‚
â”‚   â€¢ Before/after scatter plots (de-identified)                             â”‚
â”‚   â€¢ Time-series: Average improvement trajectory (weeks 0-52)               â”‚
â”‚   â€¢ HRV trends: Daily average across cohort                                â”‚
â”‚   â€¢ Guest satisfaction trends over time                                    â”‚
â”‚                                                                             â”‚
â”‚   Interactive Features:                                                    â”‚
â”‚   â€¢ Filter by: program length, age range, primary concern                  â”‚
â”‚   â€¢ Compare cohorts: Early guests vs recent guests (quality improvement)   â”‚
â”‚   â€¢ Download anonymized dataset (for researchers)                          â”‚
â”‚                                                                             â”‚
â”‚   Platform: Custom dashboard (React + D3.js) or Tableau Public             â”‚
â”‚   Update Frequency: Monthly                                                â”‚
â”‚                                                                             â”‚
â”‚   Competitive Advantage:                                                   â”‚
â”‚   No competitor publishes real outcome data. This is radical transparency. â”‚
â”‚   Builds trust. Attracts quality guests. Creates media hooks.              â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

#### Institutional Partnerships (Research)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                                                                             â”‚
â”‚   TARGET RESEARCH PARTNERSHIPS                                             â”‚
â”‚                                                                             â”‚
â”‚   TIER 1: Leading Psychedelic Research Centers                            â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   Johns Hopkins Center for Psychedelic & Consciousness Research            â”‚
â”‚   â€¢ Director: Dr. Roland Griffiths (emeritus)                              â”‚
â”‚   â€¢ Opportunity: Collaborate on ibogaine protocols                         â”‚
â”‚   â€¢ Value Exchange: We provide real-world data, they provide expertise     â”‚
â”‚                                                                             â”‚
â”‚   UCSF Neuroscape & Psychedelic Research Group                             â”‚
â”‚   â€¢ Director: Dr. Adam Gazzaley (neuroscience, tech + psychedelics)        â”‚
â”‚   â€¢ Opportunity: Biometric integration research                            â”‚
â”‚   â€¢ Value Exchange: Access to our HRV/sleep data, co-publication           â”‚
â”‚                                                                             â”‚
â”‚   Imperial College London - Centre for Psychedelic Research                â”‚
â”‚   â€¢ Director: Dr. David Nutt, Dr. Robin Carhart-Harris                     â”‚
â”‚   â€¢ Opportunity: Global psychedelic therapy standards                      â”‚
â”‚   â€¢ Value Exchange: European expansion insights, research credibility      â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   TIER 2: Trauma & Integration Specialists                                â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   Polyvagal Institute (Dr. Stephen Porges)                                 â”‚
â”‚   â€¢ Opportunity: Validate polyvagal-informed protocols                     â”‚
â”‚   â€¢ Measurement: HRV as proxy for vagal tone improvement                   â”‚
â”‚                                                                             â”‚
â”‚   Trauma Research Foundation (Dr. Bessel van der Kolk)                     â”‚
â”‚   â€¢ Opportunity: Somatic + psychedelic integration research                â”‚
â”‚   â€¢ Value: Credibility in trauma treatment space                           â”‚
â”‚                                                                             â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                             â”‚
â”‚   PARTNERSHIP STRUCTURE                                                    â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚   â€¢ MOU (Memorandum of Understanding) for data sharing                     â”‚
â”‚   â€¢ IRB approval through partner institution (easier than independent)     â”‚
â”‚   â€¢ Co-authorship on publications                                          â”‚
â”‚   â€¢ Guest referrals (researchers send clients to us)                       â”‚
â”‚   â€¢ Training exchange (we train in protocols, they train in research)      â”‚
â”‚                                                                             â”‚
â”‚   Financial Model:                                                         â”‚
â”‚   â€¢ No direct payment to partners                                          â”‚
â”‚   â€¢ Academic prestige + publication credit is compensation                 â”‚
â”‚   â€¢ We cover: Data collection costs, REDCap licenses, coordinator salary   â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

